Bennett Selby Investments LP Has $3.12 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Bennett Selby Investments LP increased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 59.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,876 shares of the company's stock after purchasing an additional 16,651 shares during the period. Novo Nordisk A/S makes up approximately 1.2% of Bennett Selby Investments LP's investment portfolio, making the stock its 19th largest holding. Bennett Selby Investments LP's holdings in Novo Nordisk A/S were worth $3,116,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. GQG Partners LLC lifted its holdings in Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $404,910,000. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC grew its position in shares of Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $158,657,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 1.1%

NVO traded up $0.82 on Monday, hitting $75.45. 10,865,984 shares of the company were exchanged, compared to its average volume of 6,921,002. The stock's fifty day moving average is $65.87 and its 200-day moving average is $80.38. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $338.59 billion, a PE ratio of 22.93, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NVO. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $128.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.